Merck Kgaa Unsp ADR (MKGAY) 33.2400 $MKGAY
EMD Millipore Announces Agreement with Precision Biologics, Inc. to Provide Upstream Process Development Services
PR Newswire - Mon Feb 02, 6:00AM CST
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, today announced an agreement for providing upstream process development services for Precision Biologics, Inc., a Texas-based clinical-stage biotechnology company, to advance a preclinical monoclonal antibody. The antibody, NEO-201, binds to a tumor-specific antigen found in several forms of cancer, offering therapeutic potential across multiple cancer types, including colorectal, lung, ovarian, and pancreatic, an especially deadly cancer with limited treatment options.
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
Symphogen Regains Rights to Sym004
Business Wire - Thu Jan 29, 3:00AM CST
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today several new corporate initiatives that reposition the company to focus on its proprietary pipeline of clinical oncology programs. The announcements address the regained rights to Sym004, a novel antibody mixture currently in a Phase 2b program, and a prioritization of the company's discovery activities in immuno-oncology.
EMD Millipore Introduces New High-Performance Water Purification Systems with 24/7 Real-Time Monitoring and Remote Control
PR Newswire - Tue Jan 27, 6:00AM CST
EMD Millipore, the Life Science business of Merck KGaA, Darmstadt, Germany, today announced the introduction of its AFS® 40E / 80E / 120E and 150E water purification systems. These new systems have been developed to provide clinical laboratories with an economical and reliable water purification solution for daily water volumes of up to 3000 L.
Lung Cancer Clinical Trial Overview 2014
M2 - Fri Jan 23, 9:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/9ww7kn/lung_cancer) has announced the addition of the "Lung Cancer Clinical Trial Overview" report to their offering. This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial metrics: - Phase of study - Study type distribution (expanded access, interventional, observational) - Length of trials - Patient enrollment - Study sponsors - Regional breakdown Major Sections: - Introduction - Lung Cancer Clinical Trial Analysis - Average Clinical Trial Enrollment - Study Sponsor Analysis by Phase - Regional Analysis How you can use this report: - Identify how products currently in development could impact this market and understand competitor involvement by using detailed information on current late phase lung cancer trials - Benchmark your study length and patient enrollment metrics against industry-wide, phase-specific, and study type-specific averages - Plan your clinical trial strategy better by understanding where industry-funded lung cancer trial sites are located globally Key Topics Covered: 1. Introduction 2. Lung cancer clinical trial analysis 3. Average length of clinical trials 4. Average Clinical Trial Enrollment 5. Study sponsor analysis by Phase 6. Regional analysis Companies Mentioned - Actavis - Agennix - Amgen - AstraZeneca - Betta Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene Corporation - Chong Kun Dang Pharmaceutical - Eisai - Eli Lilly and Company - EMD Serono - Genentech - Gilead Sciences - GlaxoSmithKline - Helsinn Therapeutics (U.S.) - Hoffmann-La Roche - J. Uriach and Company - Janssen Korea - Jiangsu HengRui Medicine Co. - Kael-GemVax Co. - Merck KGaA - Novartis Pharmaceuticals - Peregrine Pharmaceuticals - Pfizer - Pierre Fabre Pharma GmbH - Sanofi - Swami Rama Cancer Hospital and Research Institute - Synta Pharmaceuticals - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/9w...ung_cancer
AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), SNTA: 2.29 (-0.03), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
Companion Diagnostics Partnering Terms & Agreements Report 2014 (Updated Edition)
M2 - Fri Jan 16, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgqn4/companion) has announced the addition of the "Companion Diagnostics Partnering Terms & Agreements" report to their offering. The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Report scope Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide. Companion Diagnostics Partnering Terms and Agreements includes: - Trends in companion diagnostics dealmaking in the biopharma industry since 2009 - Analysis of companion diagnostics deal structure - Access to headline, upfront, milestone and royalty data - Case studies of real-life companion diagnostics deals - Access to companion diagnostics contract documents - The leading companion diagnostics deals by value since 2009 - Most active companion diagnostics dealmakers since 2009 - The leading companion diagnostics partnering resources In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by: - Company A-Z - Headline value - Stage of development at signing - Deal component type - Specific therapy target The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 250 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following: - What are the precise companion diagnostics rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Companies Mentioned - Abbott - Amgen - Astellas - AstraZeneca - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Chugai Pharmaceutical - Eisai - Eli Lilly - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Novartis - Pfizer - Roche - Sanofi - Servier - Takeda - UCB For more information visit http://www.researchandmarkets.com/research/kwgqn4/companion
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Research and Markets: PharmaPoint Report: Colorectal Cancer - Current and Future Players: Roche/Genentech, Sanofi, Eli Lilly and Co, Merck KGaA, Bayer & Taiho Pharmaceutical
Business Wire - Fri Jan 09, 9:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvxdvf/pharmapoint) has announced the addition of the "PharmaPoint: Colorectal Cancer - Current and Future Players" report to their offering.
LLY: 70.56 (+0.03)
PharmaPoint Report: Colorectal Cancer - Current and Future Players: Roche/Genentech, Sanofi, Eli Lilly and Co, Merck KGaA, Bayer & Taiho Pharmaceutical
M2 - Fri Jan 09, 8:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/8c88ns/pharmapoint) has announced the addition of the "PharmaPoint: Colorectal Cancer - Current and Future Players" report to their offering. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Colorectal Cancer Market. The report identifies and analyses the key companies shaping and driving the global Colorectal Cancer market. The report provides insight into the competitive Colorectal Cancer landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Colorectal Cancer - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Colorectal Cancer sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Roche/Genentech - Sanofi - Eli Lilly and Company - Merck KGaA - Bayer - Taiho Pharmaceutical For more information visit http://www.researchandmarkets.com/research/8c...harmapoint
LLY: 70.56 (+0.03)
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/4w44d4/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited - Merck KGaA - iCo Therapeutics Inc. - Mologen AG - Advinus Therapeutics Ltd. - Dafra Pharma International Ltd. - PolyTherics Limited For more information visit http://www.researchandmarkets.com/research/4w...shmaniasis
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Sigma-Aldrich Buyout by Merck KGaA Gets Antitrust Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:30AM CST
Sigma-Aldrich Corporation (SIAL) and Merck KGaA (MKGAY) announced that latter has obtained antitrust clearance from the US FTC for its previously announced acquisition of Sigma-Aldrich.
ROC: 79.20 (+0.33), SIAL: 138.20 (+0.07), MTX: 71.19 (+0.15)
Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance
PR Newswire - Tue Dec 23, 8:44AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with the acquisition expired on December 22, 2014, thereby completing the U.S. HSR Act antitrust notification and review requirement for the acquisition of the Company by Merck KGaA, Darmstadt, Germany.
SIAL: 138.20 (+0.07)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Photoresists and Photoresist Ancillaries Market for Semiconductors & Integrated Circuits, Printed Circuit Boards and Other Applications - 2014 Global Industry Analysis
M2 - Tue Dec 16, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/fpxq7k/photoresists_and) has announced the addition of the "Photoresists and Photoresist Ancillaries Market for Semiconductors & Integrated Circuits, Printed Circuit Boards and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Growth in the global semiconductor industry is anticipated to drive the photoresists and photoresist ancillaries market worldwide. Photoresists are indispensable components in the process of multi-layer wiring configuration in semiconductor manufacturing and high density packaging. Trends in dynamic display technologies are further estimated to boost the photoresists and photoresist ancillaries market in the near future. However, environmental and occupational health hazards associated with photoresists and photoresist ancillaries are expected to hamper the global market growth in the near future. Upcoming nanoelectromechanical systems (NEMS) are projected to offer high opportunities for market players in the next few years. In terms of revenue, semiconductor & integrated circuits (ICs) emerged as the largest application segment of the global photoresists and photoresist ancillaries market in 2013. The segment accounted for over 55% share in 2013. Semiconductor & ICs segment is anticipated to remain the largest application in the near future. Major end-use industries for semiconductor & ICs application segment include data processing (laptops, servers and personal computers), communication (smartphones, mobile phones, broadband internet and fixed-line telephones), automotive, consumer electronics (music players, household appliances and gaming consoles) and industrial electronics. Printed circuit boards was the second-largest segment for photoresists and photoresist ancillaries in 2013. Demand for photoresists and photoresist ancillaries from other applications that include MEMS, NEMS and sensors is projected to rise at a moderate pace in the next few years. Scope of the Report Photoresists Market - Product Segment Analysis - g-line and i-line - KrF - ArF dry - ArF immersion Photoresist Ancillaries Market - Product Segment Analysis - Antireflective coatings - Photoresist developers - Edge bead removers - Others (Including primers or adhesion promoters and specialty solvents) Photoresists and Photoresist Ancillaries Market - Application Analysis - Semiconductors and integrated circuits (ICs) - Printed circuit boards (PCB) - Others (Including MEMS, NEMS, sensors etc.) Companies Mentioned - Avantor Performance Materials Inc. - E. I. du Pont de Nemours and Company - FUJIFILM Electronics Materials Co. Ltd. - JSR Corporation - LG Chem Ltd - Merck KGaA - Shin-Etsu Chemical Co. Ltd. - Sumitomo Chemical Co. Ltd. - TOKYO OHKA KOGYO CO. LTD. - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/fp...esists_and
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/kspvsg/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Genentech, Inc. - MedImmune, LLC - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Merck KGaA - Oncolytics Biotech Inc. - Panacea Biotec Limited - PCI Biotech AS - Glycotope GmbH - VentiRx Pharmaceuticals, Inc. - Immunovative Therapies, Ltd. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/ks...rrent_head
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), NVS: 102.20 (-0.17)
EMD Serono Continues Leadership Role in Product Integrity by Launching Product Tracking Program and Check My Meds(TM) Smartphone App
PR Newswire - Wed Dec 10, 7:00AM CST
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced that it has serialized all of its major brands in the U.S., which helps patients and physicians to authenticate the company's medicines at the unit level. This new serialization initiative builds on the company's track record of product integrity and will launch in advance of requirements set forth in new legislation for pharmaceutical companies to serialize their prescription drug products at the unit level by 2017.
Global Cellular Imaging Markets Report 2014
M2 - Wed Dec 10, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/tj5773/cellular_imaging) has announced the addition of the "Global Cellular Imaging Markets Report 2014" report to their offering. The Global Cellular Imaging Market is dominated by Beckton Dickinson and Company, Danaher Corporation, Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., GE Healthcare, Merck KGAA, Olympus Corpopration, Perkinelmer, Inc., Promega Corporation. The global cell analysis market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Most of the players in the cell analysis instruments market are collaborating with companies and educational institutes in order to offer the products with better software also. The cell analysis market is expected to grow steadily in the forecast period. The major factor driving the growth is improved accuracy of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing prevalence of cancer, getting help from the government bodies in the form of investments, funds and grants, improved informatics services, availability of better reagents and image analysis instruments are propelling the growth of the market. However, the major market restraints include enormous capital investments and shortage of skilled labor for high content screening procedure. The biggest opportunities for this market is the growing APAC market, high content screening services provided by CRO's, automation in cancer research for its early detection and reducing cost of the cancer treatment. Key Topics Covered: 1. Executive summary 2. Introduction 3. Market Analysis 4. Single cell analysis market by technology 5. Single cell analysis market by products 6. Single cell analysis market by field of study 7. Single cell analysis market by applications 8. Single cell analysis market by end users 9. Regional Market Analysis 10. Company Developments 11. Major Company Profiles - Agilent Technologies, Inc. - Beckton, Dickinson And Company - Danaher Corporation - GE Healthcare - Merck KGaA - Olympus Corpopration - Perkinelmer, Inc - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/tj...ar_imaging
A: 40.15 (+0.13), SIAL: 138.20 (+0.07), DHR: 86.81 (+0.21)
Global Pollen Allergy Clinical Trials Review Report 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/ml2jdj/pollen_allergy) has announced the addition of the "Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Merck KGaA - Laboratorios LETI S.L. - Merck & Co., Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Circassia Pharmaceuticals plc - Anergis SA Clinical Trial Overview of Top Institutes / Government - Chiba University - University of Yamanashi - Nippon Medical School Hospital - University of Zurich - Medical University of Vienna - Imperial College London - Johann Wolfgang Goethe University Hospitals - Jikei University School of Medicine - The University of Tokushima - University of Fukui For more information visit http://www.researchandmarkets.com/research/ml...en_allergy
MRK: 58.81 (-0.07)
Sigma-Aldrich's stockholders grants approval for its USD140/share acquisition by Merck KGaA
M2 - Mon Dec 08, 6:59AM CST
Sigma-Aldrich (NASDAQ:SIAL) said on Friday that its stockholders have voted to adopt the merger agreement with and into Merck KGaA, Darmstadt, Germany at a special meeting of stockholders held earlier today.
SIAL: 138.20 (+0.07)
EMD Millipore Announces Agreement with Precision Biologics, Inc. to Provide Upstream Process Development Services
PR Newswire - Mon Feb 02, 6:00AM CST
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, today announced an agreement for providing upstream process development services for Precision Biologics, Inc., a Texas-based clinical-stage biotechnology company, to advance a preclinical monoclonal antibody. The antibody, NEO-201, binds to a tumor-specific antigen found in several forms of cancer, offering therapeutic potential across multiple cancer types, including colorectal, lung, ovarian, and pancreatic, an especially deadly cancer with limited treatment options.
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
Symphogen Regains Rights to Sym004
Business Wire - Thu Jan 29, 3:00AM CST
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today several new corporate initiatives that reposition the company to focus on its proprietary pipeline of clinical oncology programs. The announcements address the regained rights to Sym004, a novel antibody mixture currently in a Phase 2b program, and a prioritization of the company's discovery activities in immuno-oncology.
EMD Millipore Introduces New High-Performance Water Purification Systems with 24/7 Real-Time Monitoring and Remote Control
PR Newswire - Tue Jan 27, 6:00AM CST
EMD Millipore, the Life Science business of Merck KGaA, Darmstadt, Germany, today announced the introduction of its AFS® 40E / 80E / 120E and 150E water purification systems. These new systems have been developed to provide clinical laboratories with an economical and reliable water purification solution for daily water volumes of up to 3000 L.
Lung Cancer Clinical Trial Overview 2014
M2 - Fri Jan 23, 9:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/9ww7kn/lung_cancer) has announced the addition of the "Lung Cancer Clinical Trial Overview" report to their offering. This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial metrics: - Phase of study - Study type distribution (expanded access, interventional, observational) - Length of trials - Patient enrollment - Study sponsors - Regional breakdown Major Sections: - Introduction - Lung Cancer Clinical Trial Analysis - Average Clinical Trial Enrollment - Study Sponsor Analysis by Phase - Regional Analysis How you can use this report: - Identify how products currently in development could impact this market and understand competitor involvement by using detailed information on current late phase lung cancer trials - Benchmark your study length and patient enrollment metrics against industry-wide, phase-specific, and study type-specific averages - Plan your clinical trial strategy better by understanding where industry-funded lung cancer trial sites are located globally Key Topics Covered: 1. Introduction 2. Lung cancer clinical trial analysis 3. Average length of clinical trials 4. Average Clinical Trial Enrollment 5. Study sponsor analysis by Phase 6. Regional analysis Companies Mentioned - Actavis - Agennix - Amgen - AstraZeneca - Betta Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene Corporation - Chong Kun Dang Pharmaceutical - Eisai - Eli Lilly and Company - EMD Serono - Genentech - Gilead Sciences - GlaxoSmithKline - Helsinn Therapeutics (U.S.) - Hoffmann-La Roche - J. Uriach and Company - Janssen Korea - Jiangsu HengRui Medicine Co. - Kael-GemVax Co. - Merck KGaA - Novartis Pharmaceuticals - Peregrine Pharmaceuticals - Pfizer - Pierre Fabre Pharma GmbH - Sanofi - Swami Rama Cancer Hospital and Research Institute - Synta Pharmaceuticals - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/9w...ung_cancer
AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), SNTA: 2.29 (-0.03), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
Companion Diagnostics Partnering Terms & Agreements Report 2014 (Updated Edition)
M2 - Fri Jan 16, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgqn4/companion) has announced the addition of the "Companion Diagnostics Partnering Terms & Agreements" report to their offering. The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Report scope Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide. Companion Diagnostics Partnering Terms and Agreements includes: - Trends in companion diagnostics dealmaking in the biopharma industry since 2009 - Analysis of companion diagnostics deal structure - Access to headline, upfront, milestone and royalty data - Case studies of real-life companion diagnostics deals - Access to companion diagnostics contract documents - The leading companion diagnostics deals by value since 2009 - Most active companion diagnostics dealmakers since 2009 - The leading companion diagnostics partnering resources In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by: - Company A-Z - Headline value - Stage of development at signing - Deal component type - Specific therapy target The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 250 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following: - What are the precise companion diagnostics rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Companies Mentioned - Abbott - Amgen - Astellas - AstraZeneca - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Chugai Pharmaceutical - Eisai - Eli Lilly - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Novartis - Pfizer - Roche - Sanofi - Servier - Takeda - UCB For more information visit http://www.researchandmarkets.com/research/kwgqn4/companion
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Research and Markets: PharmaPoint Report: Colorectal Cancer - Current and Future Players: Roche/Genentech, Sanofi, Eli Lilly and Co, Merck KGaA, Bayer & Taiho Pharmaceutical
Business Wire - Fri Jan 09, 9:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvxdvf/pharmapoint) has announced the addition of the "PharmaPoint: Colorectal Cancer - Current and Future Players" report to their offering.
LLY: 70.56 (+0.03)
PharmaPoint Report: Colorectal Cancer - Current and Future Players: Roche/Genentech, Sanofi, Eli Lilly and Co, Merck KGaA, Bayer & Taiho Pharmaceutical
M2 - Fri Jan 09, 8:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/8c88ns/pharmapoint) has announced the addition of the "PharmaPoint: Colorectal Cancer - Current and Future Players" report to their offering. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Colorectal Cancer Market. The report identifies and analyses the key companies shaping and driving the global Colorectal Cancer market. The report provides insight into the competitive Colorectal Cancer landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Colorectal Cancer - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Colorectal Cancer sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Roche/Genentech - Sanofi - Eli Lilly and Company - Merck KGaA - Bayer - Taiho Pharmaceutical For more information visit http://www.researchandmarkets.com/research/8c...harmapoint
LLY: 70.56 (+0.03)
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/4w44d4/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited - Merck KGaA - iCo Therapeutics Inc. - Mologen AG - Advinus Therapeutics Ltd. - Dafra Pharma International Ltd. - PolyTherics Limited For more information visit http://www.researchandmarkets.com/research/4w...shmaniasis
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Sigma-Aldrich Buyout by Merck KGaA Gets Antitrust Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:30AM CST
Sigma-Aldrich Corporation (SIAL) and Merck KGaA (MKGAY) announced that latter has obtained antitrust clearance from the US FTC for its previously announced acquisition of Sigma-Aldrich.
ROC: 79.20 (+0.33), SIAL: 138.20 (+0.07), MTX: 71.19 (+0.15)
Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance
PR Newswire - Tue Dec 23, 8:44AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with the acquisition expired on December 22, 2014, thereby completing the U.S. HSR Act antitrust notification and review requirement for the acquisition of the Company by Merck KGaA, Darmstadt, Germany.
SIAL: 138.20 (+0.07)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Photoresists and Photoresist Ancillaries Market for Semiconductors & Integrated Circuits, Printed Circuit Boards and Other Applications - 2014 Global Industry Analysis
M2 - Tue Dec 16, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/fpxq7k/photoresists_and) has announced the addition of the "Photoresists and Photoresist Ancillaries Market for Semiconductors & Integrated Circuits, Printed Circuit Boards and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Growth in the global semiconductor industry is anticipated to drive the photoresists and photoresist ancillaries market worldwide. Photoresists are indispensable components in the process of multi-layer wiring configuration in semiconductor manufacturing and high density packaging. Trends in dynamic display technologies are further estimated to boost the photoresists and photoresist ancillaries market in the near future. However, environmental and occupational health hazards associated with photoresists and photoresist ancillaries are expected to hamper the global market growth in the near future. Upcoming nanoelectromechanical systems (NEMS) are projected to offer high opportunities for market players in the next few years. In terms of revenue, semiconductor & integrated circuits (ICs) emerged as the largest application segment of the global photoresists and photoresist ancillaries market in 2013. The segment accounted for over 55% share in 2013. Semiconductor & ICs segment is anticipated to remain the largest application in the near future. Major end-use industries for semiconductor & ICs application segment include data processing (laptops, servers and personal computers), communication (smartphones, mobile phones, broadband internet and fixed-line telephones), automotive, consumer electronics (music players, household appliances and gaming consoles) and industrial electronics. Printed circuit boards was the second-largest segment for photoresists and photoresist ancillaries in 2013. Demand for photoresists and photoresist ancillaries from other applications that include MEMS, NEMS and sensors is projected to rise at a moderate pace in the next few years. Scope of the Report Photoresists Market - Product Segment Analysis - g-line and i-line - KrF - ArF dry - ArF immersion Photoresist Ancillaries Market - Product Segment Analysis - Antireflective coatings - Photoresist developers - Edge bead removers - Others (Including primers or adhesion promoters and specialty solvents) Photoresists and Photoresist Ancillaries Market - Application Analysis - Semiconductors and integrated circuits (ICs) - Printed circuit boards (PCB) - Others (Including MEMS, NEMS, sensors etc.) Companies Mentioned - Avantor Performance Materials Inc. - E. I. du Pont de Nemours and Company - FUJIFILM Electronics Materials Co. Ltd. - JSR Corporation - LG Chem Ltd - Merck KGaA - Shin-Etsu Chemical Co. Ltd. - Sumitomo Chemical Co. Ltd. - TOKYO OHKA KOGYO CO. LTD. - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/fp...esists_and
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/kspvsg/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Genentech, Inc. - MedImmune, LLC - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Merck KGaA - Oncolytics Biotech Inc. - Panacea Biotec Limited - PCI Biotech AS - Glycotope GmbH - VentiRx Pharmaceuticals, Inc. - Immunovative Therapies, Ltd. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/ks...rrent_head
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), NVS: 102.20 (-0.17)
EMD Serono Continues Leadership Role in Product Integrity by Launching Product Tracking Program and Check My Meds(TM) Smartphone App
PR Newswire - Wed Dec 10, 7:00AM CST
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced that it has serialized all of its major brands in the U.S., which helps patients and physicians to authenticate the company's medicines at the unit level. This new serialization initiative builds on the company's track record of product integrity and will launch in advance of requirements set forth in new legislation for pharmaceutical companies to serialize their prescription drug products at the unit level by 2017.
Global Cellular Imaging Markets Report 2014
M2 - Wed Dec 10, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/tj5773/cellular_imaging) has announced the addition of the "Global Cellular Imaging Markets Report 2014" report to their offering. The Global Cellular Imaging Market is dominated by Beckton Dickinson and Company, Danaher Corporation, Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., GE Healthcare, Merck KGAA, Olympus Corpopration, Perkinelmer, Inc., Promega Corporation. The global cell analysis market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Most of the players in the cell analysis instruments market are collaborating with companies and educational institutes in order to offer the products with better software also. The cell analysis market is expected to grow steadily in the forecast period. The major factor driving the growth is improved accuracy of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing prevalence of cancer, getting help from the government bodies in the form of investments, funds and grants, improved informatics services, availability of better reagents and image analysis instruments are propelling the growth of the market. However, the major market restraints include enormous capital investments and shortage of skilled labor for high content screening procedure. The biggest opportunities for this market is the growing APAC market, high content screening services provided by CRO's, automation in cancer research for its early detection and reducing cost of the cancer treatment. Key Topics Covered: 1. Executive summary 2. Introduction 3. Market Analysis 4. Single cell analysis market by technology 5. Single cell analysis market by products 6. Single cell analysis market by field of study 7. Single cell analysis market by applications 8. Single cell analysis market by end users 9. Regional Market Analysis 10. Company Developments 11. Major Company Profiles - Agilent Technologies, Inc. - Beckton, Dickinson And Company - Danaher Corporation - GE Healthcare - Merck KGaA - Olympus Corpopration - Perkinelmer, Inc - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/tj...ar_imaging
A: 40.15 (+0.13), SIAL: 138.20 (+0.07), DHR: 86.81 (+0.21)
Global Pollen Allergy Clinical Trials Review Report 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/ml2jdj/pollen_allergy) has announced the addition of the "Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Merck KGaA - Laboratorios LETI S.L. - Merck & Co., Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Circassia Pharmaceuticals plc - Anergis SA Clinical Trial Overview of Top Institutes / Government - Chiba University - University of Yamanashi - Nippon Medical School Hospital - University of Zurich - Medical University of Vienna - Imperial College London - Johann Wolfgang Goethe University Hospitals - Jikei University School of Medicine - The University of Tokushima - University of Fukui For more information visit http://www.researchandmarkets.com/research/ml...en_allergy
MRK: 58.81 (-0.07)
Sigma-Aldrich's stockholders grants approval for its USD140/share acquisition by Merck KGaA
M2 - Mon Dec 08, 6:59AM CST
Sigma-Aldrich (NASDAQ:SIAL) said on Friday that its stockholders have voted to adopt the merger agreement with and into Merck KGaA, Darmstadt, Germany at a special meeting of stockholders held earlier today.
SIAL: 138.20 (+0.07)
